Comments on:

FDA must decide if a biosimilar rose by any other name is still a rose

Back to the article » |
"A good name is better than precious ointment." – Ecclesiastes 7:1 Federal approval of biosimilars promises to be a very good thing, but the devil is in the details. Unfortunately, we’re seeing a disturbing trend relating to one of those key details: naming nomenclature. Biosimilars are biological drugs that are similar, but not identical, to the original FDA-approved medicines. Advocates for...

To learn more about commenting on and our community guidelines, please see our comments FAQ.